

# MD7511Advanced Injectable Therapies

## Injectable Therapies

View Online



1.  
Type 2 Diabetes Therapies and Management : an Educational Toolkit,  
[https://blackboard.le.ac.uk/bbcswebdav/courses/MB7501/UHL\\_LDC\\_Leicester\\_Diabetes\\_Type2\\_Therapies\\_3rd\\_Ed\\_23July2018.pdf](https://blackboard.le.ac.uk/bbcswebdav/courses/MB7501/UHL_LDC_Leicester_Diabetes_Type2_Therapies_3rd_Ed_23July2018.pdf).
  
2.  
Insulin Therapies: An Educational Toolkit,  
[https://blackboard.le.ac.uk/bbcswebdav/courses/MB7501/UHL\\_LDC\\_Leicester\\_Insulin\\_Therapies\\_3rd\\_Ed\\_16July2018\\_F.pdf](https://blackboard.le.ac.uk/bbcswebdav/courses/MB7501/UHL_LDC_Leicester_Insulin_Therapies_3rd_Ed_16July2018_F.pdf).
  
3.  
Holt, R.I.G., Cockram, C., Flyvbjerg, A., Goldstein, B.J.: Textbook of Diabetes. John Wiley & Sons, Incorporated, Somerset (2016).
  
4.  
Holt, R.I.G.: Textbook of diabetes. Wiley-Blackwell, Chichester (2010).
  
5.  
Craeto, W.: Handbook of Insulin Therapies. Adis; 1st ed. 2016 edition (2016).
  
6.  
Efficacy and Safety of Glucagon-like peptide-1 receptor agonists in type 2 diabetes  
Systematic review and mixed-treatment comparison analysis.

7.

Holt, R.I.G., Cockram, C., Flyvbjerg, A., Goldstein, B.J.: Textbook of Diabetes. John Wiley & Sons, Incorporated, Somerset (2016).

8.

Holt, R.I.G.: Textbook of diabetes. Wiley-Blackwell, Chichester (2010).

9.

Evans, M., Schumm-Draeger, P.M., Vora, J., King, A.B.: A review of modern insulin analogue pharmacokinetic and pharmacodynamic profiles in type 2 diabetes: improvements and limitations. *Diabetes, Obesity and Metabolism*. 13, 677–684 (2011).

<https://doi.org/10.1111/j.1463-1326.2011.01395.x>.

10.

Nauck, M.: Incretin therapies: highlighting common features and differences in the modes of action of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors. *Diabetes, Obesity and Metabolism*. 18, 203–216 (2016).

<https://doi.org/10.1111/dom.12591>.

11.

Ismail-Beigi, F.: Glycemic Management of Type 2 Diabetes Mellitus. *New England Journal of Medicine*. 366, 1319–1327 (2012). <https://doi.org/10.1056/NEJMcp1013127>.

12.

Nathan, D.M., Buse, J.B., Davidson, M.B., Heine, R.J., Holman, R.R., Sherwin, R., Zinman, B.: Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. *Diabetes Care*. 29, 1963–1972 (2006). <https://doi.org/10.2337/dc06-9912>.

13.

Srinivasan, B.T., Davies, M.: Glycaemic management of type 2 diabetes. *Medicine*. 42, 711–717 (2014). <https://doi.org/10.1016/j.mpmed.2014.09.011>.

14.

Srinivasan, B.T., Jarvis, J., Khunti, K., Davies, M.J.: Recent advances in the management of type 2 diabetes mellitus: a review. *Postgraduate Medical Journal*. 84, 524–531 (2008). <https://doi.org/10.1136/pgmj.2008.067918>.

15.

Home, P.D.: The pharmacokinetics and pharmacodynamics of rapid-acting insulin analogues and their clinical consequences. *Diabetes, Obesity and Metabolism*. 14, 780–788 (2012). <https://doi.org/10.1111/j.1463-1326.2012.01580.x>.

16.

June James: Safety and insulin: implementation of national guidance at a local level. *Journal of Diabetes Nursing*.

17.

Rorsman, P., Renström, E.: Insulin granule dynamics in pancreatic beta cells. *Diabetologia*. 46, 1029–1045 (2003). <https://doi.org/10.1007/s00125-003-1153-1>.

18.

L. Luzi: Effect of loss of first-phase insulin secretion on hepatic glucose production and tissue glucose disposal in humans. *American Journal of Physiology - Endocrinology and Metabolism*. 257, E241–E246 (1989).

19.

Luc JC van Loon: Plasma insulin responses after ingestion of different amino acid or protein mixtures with carbohydrate. *The American Journal of Clinical Nutrition*. 72, 96–105 (2000).

20.

Menting, J.G., Whittaker, J., Margetts, M.B., Whittaker, L.J., Kong, G.K.-W., Smith, B.J., Watson, C.J., Žáková, L., Kletvíková, E., Jiráček, J., Chan, S.J., Steiner, D.F., Dodson, G.G., Brzozowski, A.M., Weiss, M.A., Ward, C.W., Lawrence, M.C.: How insulin engages its primary binding site on the insulin receptor. *Nature*. 493, 241–245 (2013). <https://doi.org/10.1038/nature11781>.

21.

Wahren, J., Kallas, A.: Loss of Pulsatile Insulin Secretion: A Factor in the Pathogenesis of Type 2 Diabetes? *Diabetes*. 61, 2228–2229 (2012). <https://doi.org/10.2337/db12-0664>.

22.

Professor Kamlesh Khunti - Coding, Classification and Diagnosis of Diabetes, <https://www.youtube.com/watch?v=AhhWTmEFuag>, (4)AD.

23.

Hermansen, K., Davies, M., Derezinski, T., Martinez Ravn, G., Clauson, P., Home, P.: A 26-Week, Randomized, Parallel, Treat-to-Target Trial Comparing Insulin Detemir With NPH Insulin as Add-On Therapy to Oral Glucose-Lowering Drugs in Insulin-Naive People With Type 2 Diabetes. *Diabetes Care*. 29, 1269–1274 (2006). <https://doi.org/10.2337/dc05-1365>.

24.

Richter, B., Neises, G.: 'Human' insulin versus animal insulin in people with diabetes mellitus. In: *Cochrane Database of Systematic Reviews*. John Wiley & Sons, Ltd, Chichester, UK (1996). <https://doi.org/10.1002/14651858.CD003816.pub2>.

25.

Holman, R.R., Turner, R.C.: A Practical Guide to Basal and Prandial Insulin Therapy. *Diabetic Medicine*. 2, 45–53 (1985). <https://doi.org/10.1111/j.1464-5491.1985.tb00592.x>.

26.

Crasto, W.: *Handbook of Insulin Therapies*. Adis; 1st ed. 2016 edition (2016).

27.

Crasto, W., Jarvis, J., Hackett, E., Nayyar, V., McNally, P.G., Davies, M.J., Lawrence, I.G.: Insulin U-500 in severe insulin resistance in type 2 diabetes mellitus. *Postgraduate Medical Journal*. 85, 219–222 (2009). <https://doi.org/10.1136/pgmj.2008.073379>.

28.

Swinnen, S.G., Simon, A.C., Holleman, F., Hoekstra, J.B., DeVries, J.H.: Insulin detemir versus insulin glargine for type 2 diabetes mellitus. In: *Cochrane Database of Systematic Reviews*. John Wiley & Sons, Ltd, Chichester, UK (1996). <https://doi.org/10.1002/14651858.CD006383.pub2>.

29.

Bretzel, R.G., Nuber, U., Landgraf, W., Owens, D.R., Bradley, C., Linn, T.: Once-daily basal insulin glargine versus thrice-daily prandial insulin lispro in people with type 2 diabetes on oral hypoglycaemic agents (APOLLO): an open randomised controlled trial. *The Lancet*. 371, 1073–1084 (2008). [https://doi.org/10.1016/S0140-6736\(08\)60485-7](https://doi.org/10.1016/S0140-6736(08)60485-7).

30.

Davies, M.J., Donnelly, R., Barnett, A.H., Jones, S., Nicolay, C., Kilcoyne, A.: Exenatide compared with long-acting insulin to achieve glycaemic control with minimal weight gain in patients with type 2 diabetes: results of the Helping Evaluate Exenatide in patients with diabetes compared with Long-Acting insulin (HEELA) study. *Diabetes, Obesity and Metabolism*. 11, 1153–1162 (2009). <https://doi.org/10.1111/j.1463-1326.2009.01154.x>.

31.

Garber, A.J., Ligthelm, R., Christiansen, J.S., Liebl, A.: Premixed insulin treatment for type 2 diabetes: analogue or human? *Diabetes, Obesity and Metabolism*. 9, 630–639 (2007). <https://doi.org/10.1111/j.1463-1326.2006.00654.x>.

32.

Holman, R.R., Thorne, K.I., Farmer, A.J., Davies, M.J., Keenan, J.F., Paul, S., Levy, J.C.: Addition of Biphasic, Prandial, or Basal Insulin to Oral Therapy in Type 2 Diabetes. *New England Journal of Medicine*. 357, 1716–1730 (2007). <https://doi.org/10.1056/NEJMoa075392>.

33.

Horvath, K., Jeitler, K., Berghold, A., Ebrahim, S.H., Gratzner, T.W., Plank, J., Kaiser, T., Pieber, T.R., Siebenhofer, A.: Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus. In: Cochrane Database of Systematic Reviews. John Wiley & Sons, Ltd, Chichester, UK (1996). <https://doi.org/10.1002/14651858.CD005613.pub3>.

34.

Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study, <http://link.springer.com.ezproxy4.lib.le.ac.uk/article/10.1007/s00125-005-0132-0/fulltext.html>.

35.

Riddle, M.C., Aronson, R., Home, P., Marre, M., Niemoeller, E., Miossec, P., Ping, L., Ye, J., Rosenstock, J.: Adding Once-Daily Lixisenatide for Type 2 Diabetes Inadequately Controlled by Established Basal Insulin: A 24-week, randomized, placebo-controlled comparison (GetGoal-L). *Diabetes Care*. 36, 2489–2496 (2013). <https://doi.org/10.2337/dc12-2454>.

36.

Gough, S.C.L., Bhargava, A., Jain, R., Mersebach, H., Rasmussen, S., Bergenstal, R.M.: Low-Volume Insulin Degludec 200 Units/mL Once Daily Improves Glycemic Control Similarly to Insulin Glargine With a Low Risk of Hypoglycemia in Insulin-Naive Patients With Type 2 Diabetes: A 26-week, randomized, controlled, multinational, treat-to-target trial: The BEGIN LOW VOLUME trial. *Diabetes Care*. 36, 2536–2542 (2013). <https://doi.org/10.2337/dc12-2329>.

37.

Hirsch, I.B., Buse, J.B., Leahy, J., McGill, J.B., Peters, A., Rodbard, H.W., Rubin, R.R., Skyler, J.S., Verderese, C.A., Riddle, M.C.: Options for prandial glucose management in type 2 diabetes patients using basal insulin: addition of a short-acting GLP-1 analogue versus progression to basal-bolus therapy. *Diabetes, Obesity and Metabolism*. 16, 206–214 (2014). <https://doi.org/10.1111/dom.12136>.

38.

Zinman, B., Fulcher, G., Rao, P.V., Thomas, N., Endahl, L.A., Johansen, T., Lindh, R., Lewin, A., Rosenstock, J., Pinget, M., Mathieu, C.: Insulin degludec, an ultra-long-acting basal insulin, once a day or three times a week versus insulin glargine once a day in patients with type 2 diabetes: a 16-week, randomised, open-label, phase 2 trial. *The Lancet*. 377, 924–931 (2011). [https://doi.org/10.1016/S0140-6736\(10\)62305-7](https://doi.org/10.1016/S0140-6736(10)62305-7).

39.

Young, L.A., Buse, J.B.: GLP-1 receptor agonists and basal insulin in type 2 diabetes. *The Lancet*. 384, 2180–2181 (2014). [https://doi.org/10.1016/S0140-6736\(14\)61409-4](https://doi.org/10.1016/S0140-6736(14)61409-4).

40.

Rosenstock, J., Raccach, D., Koranyi, L., Maffei, L., Boka, G., Miossec, P., Gerich, J.E.: Efficacy and Safety of Lixisenatide Once Daily Versus Exenatide Twice Daily in Type 2 Diabetes Inadequately Controlled on Metformin: A 24-week, randomized, open-label, active-controlled study (GetGoal-X). *Diabetes Care*. 36, 2945–2951 (2013). <https://doi.org/10.2337/dc12-2709>.

41.

Diamant, M., Van Gaal, L., Stranks, S., Northrup, J., Cao, D., Taylor, K., Trautmann, M.: Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial. *The Lancet*. 375, 2234–2243 (2010). [https://doi.org/10.1016/S0140-6736\(10\)60406-0](https://doi.org/10.1016/S0140-6736(10)60406-0).

42.

New IDegLira data show rapid and predictable glycaemic improvements in people with type 2 diabetes,  
<http://www.multivu.com/players/English/72762519-novo-nordisk-IDegLira-treatment/>.

43.

Horvath, K., Jeitler, K., Berghold, A., Ebrahim, S.H., Gratzner, T.W., Plank, J., Kaiser, T., Pieber, T.R., Siebenhofer, A.: Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus. In: *Cochrane Database of Systematic Reviews*. John Wiley & Sons, Ltd, Chichester, UK (1996). <https://doi.org/10.1002/14651858.CD005613.pub3>.

44.

Buse, J.B., Bergenstal, R.M., Glass, L.C., Heilmann, C.R., Lewis, M.S., Kwan, A.Y.M., Hoogwerf, B.J., Rosenstock, J.: Use of Twice-Daily Exenatide in Basal Insulin-Treated Patients With Type 2 Diabetes. *Annals of Internal Medicine*. 154, (2011). <https://doi.org/10.7326/0003-4819-154-2-201101180-00300>.

45.

Rosenstock, J., Jelaska, A., Frappin, G., Salsali, A., Kim, G., Woerle, H.J., Broedl, U.C.: Improved Glucose Control With Weight Loss, Lower Insulin Doses, and No Increased Hypoglycemia With Empagliflozin Added to Titrated Multiple Daily Injections of Insulin in Obese Inadequately Controlled Type 2 Diabetes. *Diabetes Care*. 37, 1815–1823 (2014). <https://doi.org/10.2337/dc13-3055>.

46.

Frandsen, C.S.S., Madsbad, S.: Efficacy and safety of dipeptidyl peptidase-4 inhibitors as an add-on to insulin treatment in patients with Type 2 diabetes: a review. *Diabetic Medicine*. 31, 1293–1300 (2014). <https://doi.org/10.1111/dme.12561>.

47.

Hirsch, I.B., Franek, E., Mersebach, H., Bardtrum, L., Hermansen, K.: Safety and efficacy of insulin degludec/insulin aspart with bolus mealtime insulin aspart compared with standard basal-bolus treatment in people with Type 1 diabetes: 1-year results from a randomized clinical trial (BOOST T1). *Diabetic Medicine*. 34, 167–173 (2017). <https://doi.org/10.1111/dme.13068>.

48.

Rodbard, H.W., Bode, B.W., Harris, S.B., Rose, L., Lehmann, L., Jarlov, H., Thurman, J.: Safety and efficacy of insulin degludec/liraglutide (IDegLira) added to sulphonylurea alone or to sulphonylurea and metformin in insulin-naïve people with Type 2 diabetes: the DUAL IV trial. *Diabetic Medicine*. 34, 189–196 (2017). <https://doi.org/10.1111/dme.13256>.

49.

Davies, M.J., Leiter, L.A., Guerci, B., Grunberger, G., Ampudia-Blasco, F.J., Yu, C., Stager, W., Niemoeller, E., Souhami, E., Rosenstock, J.: Impact of baseline HbA1c, diabetes duration and BMI on clinical outcomes in the LixiLan-O trial testing iGlarLixi (insulin glargine/lixisenatide titratable fixed-ratio combination) versus insulin glargine and



lixisenatide monocomponents. *Diabetes, Obesity and Metabolism*. (2017).  
<https://doi.org/10.1111/dom.12980>.

50.

Raccah, D., Huet, D., Dib, A., Joseph, F., Landers, B., Escalada, J., Schmitt, H.: Review of basal-plus insulin regimen options for simpler insulin intensification in people with Type 2 diabetes mellitus. *Diabetic Medicine*. (2017). <https://doi.org/10.1111/dme.13390>.

51.

Daly, H., Davies, M., Barnett, J., Amin, S., Gray, G., Leonard, J., Northern, A., Crasto, W., Khunti, K., Jarvis, J.: Development of a self-management education module for those with type 2 diabetes on injectable therapies. *Practical Diabetes*. 32, 305–310a (2015).  
<https://doi.org/10.1002/pdi.1979>.

52.

Crasto, W.: *Handbook of Insulin Therapies*. Adis; 1st ed. 2016 edition (2016).

53.

A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naïve people with type 2 diabetes,  
<http://link.springer.com.ezproxy4.lib.le.ac.uk/article/10.1007/s00125-007-0911-x/fulltext.html>.

54.

Hannele Yki-Jarvinen, Leena Juurinen, Michael Alvarsson, Tord Bystedt, Ian Caldwell, Melanie Davies: Initiate insulin by aggressive titration and education (Initiate): randomized study to compare initiation of insulin combination therapy in type 2 diabetic patients individually and in groups. *Diabetes Care*.

55.

Philip Raskin, Elsie Allen, Priscilla Hollander, Andrew Lewin, Robert A. Gabbay, Peter Hu: Initiating insulin therapy in type 2 diabetes: a comparison of biphasic and basal insulin analogs. *Diabetes Care*.

56.

Holman, R.R., Paul, S.K., Bethel, M.A., Matthews, D.R., Neil, H.A.W.: 10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes. *New England Journal of Medicine*. 359, 1577–1589 (2008). <https://doi.org/10.1056/NEJMoa0806470>.

57.

Basal Insulin and Cardiovascular and Other Outcomes in Dysglycemia. *New England Journal of Medicine*. 367, 319–328 (2012). <https://doi.org/10.1056/NEJMoa1203858>.

58.

Goudswaard, A.N., Furlong, N.J., Valk, G.D., Stolk, R.P., Rutten, G.E.: Insulin monotherapy versus combinations of insulin with oral hypoglycaemic agents in patients with type 2 diabetes mellitus. In: *Cochrane Database of Systematic Reviews*. John Wiley & Sons, Ltd, Chichester, UK (1996). <https://doi.org/10.1002/14651858.CD003418.pub2>.

59.

Kramer, C.K., Zinman, B., Retnakaran, R.: Short-term intensive insulin therapy in type 2 diabetes mellitus: a systematic review and meta-analysis. *The Lancet Diabetes & Endocrinology*. 1, 28–34 (2013). [https://doi.org/10.1016/S2213-8587\(13\)70006-8](https://doi.org/10.1016/S2213-8587(13)70006-8).

60.

Holman, R.R., Farmer, A.J., Davies, M.J., Levy, J.C., Darbyshire, J.L., Keenan, J.F., Paul, S.K.: Three-Year Efficacy of Complex Insulin Regimens in Type 2 Diabetes. *New England Journal of Medicine*. 361, 1736–1747 (2009). <https://doi.org/10.1056/NEJMoa0905479>.

61.

Yki-Jarvinen, H., Juurinen, L., Alvarsson, M., Bystedt, T., Caldwell, I., Davies, M., Lahdenpera, S., Nijpels, G., Vahatalo, M.: Initiate Insulin by Aggressive Titration and Education (INITIATE): A randomized study to compare initiation of insulin combination therapy in type 2 diabetic patients individually and in groups. *Diabetes Care*. 30, 1364–1369 (2007). <https://doi.org/10.2337/dc06-1357>.

62.

Davies, M., Storms, F., Shutler, S., Bianchi-Biscay, M., Gomis, R.: Improvement of Glycemic Control in Subjects With Poorly Controlled Type 2 Diabetes: Comparison of two treatment algorithms using insulin glargine. *Diabetes Care*. 28, 1282–1288 (2005). <https://doi.org/10.2337/diacare.28.6.1282>.

63.

Eng, C., Kramer, C.K., Zinman, B., Retnakaran, R.: Glucagon-like peptide-1 receptor agonist and basal insulin combination treatment for the management of type 2 diabetes: a systematic review and meta-analysis. *The Lancet*. 384, 2228–2234 (2014). [https://doi.org/10.1016/S0140-6736\(14\)61335-0](https://doi.org/10.1016/S0140-6736(14)61335-0).

64.

Yki-Jarvinen, H., Kotronen, A.: Is There Evidence to Support Use of Premixed or Prandial Insulin Regimens in Insulin-Naive or Previously Insulin-Treated Type 2 Diabetic Patients? *Diabetes Care*. 36, S205–S211 (2013). <https://doi.org/10.2337/dcS13-2026>.

65.

Lasserson, D.S., Glasziou, P., Perera, R., Holman, R.R., Farmer, A.J.: Optimal insulin regimens in type 2 diabetes mellitus: systematic review and meta-analyses. *Diabetologia*. 52, 1990–2000 (2009). <https://doi.org/10.1007/s00125-009-1468-7>.

66.

Wang, C., Mamza, J., Idris, I.: Biphasic vs basal bolus insulin regimen in Type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. *Diabetic Medicine*. 32, 585–594 (2015). <https://doi.org/10.1111/dme.12694>.

67.

Davies, M.J., Chatterjee, S.: Trial watch: Insulin initiation for type 2 diabetes mellitus in primary care. *Nature Reviews Endocrinology*. 13, 317–318 (2017). <https://doi.org/10.1038/nrendo.2017.41>.

68.

Clinical effectiveness and cost-effectiveness of continuous subcutaneous insulin infusion for diabetes: systematic review and economic evaluation.

69.

Crasto, W.: Handbook of Insulin Therapies. Adis; 1st ed. 2016 edition (2016).

70.

Heller, S., Buse, J., Fisher, M., Garg, S., Marre, M., Merker, L., Renard, E., Russell-Jones, D., Philotheou, A., Francisco, A.M.O., Pei, H., Bode, B.: Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial. *The Lancet*. 379, 1489–1497 (2012). [https://doi.org/10.1016/S0140-6736\(12\)60204-9](https://doi.org/10.1016/S0140-6736(12)60204-9).

71.

Davies, M.J., Gross, J.L., Ono, Y., Sasaki, T., Bantwal, G., Gall, M.A., Niemeyer, M., Seino, H.: Efficacy and safety of insulin degludec given as part of basal-bolus treatment with mealtime insulin aspart in type 1 diabetes: a 26-week randomized, open-label, treat-to-target non-inferiority trial. *Diabetes, Obesity and Metabolism*. 16, 922–930 (2014). <https://doi.org/10.1111/dom.12298>.

72.

Ashwell, S.G., Amiel, S.A., Bilous, R.W., Dashora, U., Heller, S.R., Hepburn, D.A., Shutler, S.D., Stephens, J.W., Home, P.D.: Improved glycaemic control with insulin glargine plus insulin lispro: a multicentre, randomized, cross-over trial in people with Type 1 diabetes. *Diabetic Medicine*. 23, 285–292 (2006). <https://doi.org/10.1111/j.1464-5491.2005.01781.x>.

73.

The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long-Term Complications in Insulin-Dependent Diabetes Mellitus. *New England Journal of Medicine*. 329, 977–986 (1993). <https://doi.org/10.1056/NEJM199309303291401>.

74.

Nathan, D.M.: The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study at 30 Years: Overview. *Diabetes Care*. 37, 9–16 (2014). <https://doi.org/10.2337/dc13-2112>.

75.

Bergenstal, R.M., Tamborlane, W.V., Ahmann, A., Buse, J.B., Dailey, G., Davis, S.N., Joyce, C., Peoples, T., Perkins, B.A., Welsh, J.B., Willi, S.M., Wood, M.A.: Effectiveness of Sensor-Augmented Insulin-Pump Therapy in Type 1 Diabetes. *New England Journal of Medicine*. 363, 311–320 (2010). <https://doi.org/10.1056/NEJMoa1002853>.

76.

Kahler, P., Grevstad, B., Almdal, T., Gluud, C., Wetterslev, J., Vaag, A., Hemmingsen, B.: Targeting intensive versus conventional glycaemic control for type 1 diabetes mellitus: a systematic review with meta-analyses and trial sequential analyses of randomised clinical trials. *BMJ Open*. 4, e004806–e004806 (2014). <https://doi.org/10.1136/bmjopen-2014-004806>.

77.

Fullerton, B., Jeitler, K., Seitz, M., Horvath, K., Berghold, A., Siebenhofer, A.: Intensive glucose control versus conventional glucose control for type 1 diabetes mellitus. In: *Cochrane Database of Systematic Reviews*. John Wiley & Sons, Ltd, Chichester, UK (1996). <https://doi.org/10.1002/14651858.CD009122.pub2>.

78.

Benkhadra, K., Alahdab, F., Tamhane, S., Wang, Z., Prokop, L.J., Hirsch, I.B., Racciah, D., Riveline, J.-P., Kordonouri, O., Murad, M.H.: Real Time Continuous Glucose Monitoring in type 1 diabetes: A Systematic review and Individual Patient Data Meta-Analysis. *Clinical Endocrinology*. (2016). <https://doi.org/10.1111/cen.13290>.

79.

McCrimmon, R.J.: Old habits are hard to break: lessons from the study of hypoglycaemia. *Diabetic Medicine*. 34, 148–155 (2017). <https://doi.org/10.1111/dme.13277>.

80.

Heller, S.R., Colagiuri, S., Vaaler, S., Wolffenbuttel, B.H.R., Koelendorf, K., Friberg, H.H., Windfeld, K., Lindholm, A.: Hypoglycaemia with insulin aspart: a double-blind, randomised, crossover trial in subjects with Type 1 diabetes. *Diabetic Medicine*. 21, 769–775 (2004). <https://doi.org/10.1111/j.1464-5491.2004.01244.x>.

81.

Pickup, J.C., Reznik, Y., Sutton, A.J.: Glycemic Control During Continuous Subcutaneous Insulin Infusion Versus Multiple Daily Insulin Injections in Type 2 Diabetes: Individual Patient Data Meta-analysis and Meta-regression of Randomized Controlled Trials. *Diabetes Care*. 40, 715–722 (2017). <https://doi.org/10.2337/dc16-2201>.

82.

Wang, W., Liu, H., Xiao, S., Liu, S., Li, X., Yu, P.: Effects of Insulin Plus Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs) in Treating Type 1 Diabetes Mellitus: A Systematic Review and Meta-Analysis. *Diabetes Therapy*. (2017). <https://doi.org/10.1007/s13300-017-0282-3>.

83.

Villani, M., de Courten, B., Zoungas, S.: Emergency treatment of hypoglycaemia: a guideline and evidence review. *Diabetic Medicine*. 34, 1205–1211 (2017). <https://doi.org/10.1111/dme.13379>.

84.

Walker, R.A., Rodgers, J., Diabetes UK.: *Diabetes: a practical guide to managing your health*. Dorling Kindersley, London (2010).

85.

Holman, R.R., Farmer, A.J., Davies, M.J., Levy, J.C., Darbyshire, J.L., Keenan, J.F., Paul, S.K.: Three-Year Efficacy of Complex Insulin Regimens in Type 2 Diabetes. *New England Journal of Medicine*. 361, 1736–1747 (2009). <https://doi.org/10.1056/NEJMoa0905479>.

86.

Hermansen, K., Davies, M.: Does insulin detemir have a role in reducing risk of insulin-associated weight gain? *Diabetes, Obesity and Metabolism*. 9, 209–217 (2007).

<https://doi.org/10.1111/j.1463-1326.2006.00665.x>.

87.

Anderson, J.W., Kendall, C.W.C., Jenkins, D.J.A.: Importance of Weight Management in Type 2 Diabetes: Review with Meta-analysis of Clinical Studies. *Journal of the American College of Nutrition*. 22, 331–339 (2003). <https://doi.org/10.1080/07315724.2003.10719316>.

88.

Russell-Jones, D., Khan, R.: Insulin-associated weight gain in diabetes – causes, effects and coping strategies. *Diabetes, Obesity and Metabolism*. 9, 799–812 (2007). <https://doi.org/10.1111/j.1463-1326.2006.00686.x>.

89.

Training in flexible, intensive insulin management to enable dietary freedom in people with type 1 diabetes: dose adjustment for normal eating (DAFNE) randomised controlled trial. *BMJ*. 325, 746–746 (2002). <https://doi.org/10.1136/bmj.325.7367.746>.

90.

Anderson, B., Funnell, M., American Diabetes Association: The art of empowerment: stories and strategies for diabetes educators. American Diabetes Association, Alexandria, Va (2005).

91.

Insulin treatment and the problem of weight gain in type 2 diabetes. - PubMed - NCBI, <http://www.ncbi.nlm.nih.gov/pubmed/17102158>.

92.

Tikkanen-Dolenc, H., Wadén, J., Forsblom, C., Harjutsalo, V., Thorn, L.M., Saraheimo, M., Elonen, N., Rosengård-Bärlund, M., Gordin, D., Tikkanen, H.O., Groop, P.-H.: Frequent and intensive physical activity reduces risk of cardiovascular events in type 1 diabetes. *Diabetologia*. (2016). <https://doi.org/10.1007/s00125-016-4189-8>.

93.

Peter Mansell: The dose adjustment for normal eating (DAFNE) education programme. *Journal of Diabetes Nursing*.

94.:

Summary of Revisions. *Diabetes Care*. 39, S4–S5 (2016).  
<https://doi.org/10.2337/dc16-S003>.

95.

Effects of Intensive Glucose Lowering in Type 2 Diabetes. *New England Journal of Medicine*. 358, 2545–2559 (2008). <https://doi.org/10.1056/NEJMoa0802743>.

96.

Garber, A.J., Wahlen, J., Wahl, T., Bressler, P., Braceras, R., Allen, E., Jain, R.: Attainment of glycaemic goals in type 2 diabetes with once-, twice-, or thrice-daily dosing with biphasic insulin aspart 70/30 (The 1-2-3 study). *Diabetes, Obesity and Metabolism*. 8, 58–66 (2006).  
<https://doi.org/10.1111/j.1463-1326.2005.00563.x>.

97.

Owens, D.R.: Stepwise intensification of insulin therapy in Type 2 diabetes management-exploring the concept of the basal-plus approach in clinical practice. *Diabetic Medicine*. 30, 276–288 (2013). <https://doi.org/10.1111/dme.12019>.

98.

Davies, M., Storms, F., Shutler, S., Bianchi-Biscay, M., Gomis, R.: Improvement of Glycemic Control in Subjects With Poorly Controlled Type 2 Diabetes: Comparison of two treatment algorithms using insulin glargine. *Diabetes Care*. 28, 1282–1288 (2005).  
<https://doi.org/10.2337/diacare.28.6.1282>.

99.

Park, S.W., Bebakar, W.M.W., Hernandez, P.G., Macura, S., Hersløv, M.L., de la Rosa, R.: Insulin degludec/insulin aspart once daily in Type 2 diabetes: a comparison of simple or stepwise titration algorithms (BOOST : SIMPLE USE). *Diabetic Medicine*.



34, 174–179 (2017). <https://doi.org/10.1111/dme.13069>.

100.

Matthew C. Riddle, Julio Rosenstock, John Gerich: The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. *Diabetes Care*.

101.

Fineman, M.S., Cirincione, B.B., Maggs, D., Diamant, M.: GLP-1 based therapies: differential effects on fasting and postprandial glucose. *Diabetes, Obesity and Metabolism*. 14, 675–688 (2012). <https://doi.org/10.1111/j.1463-1326.2012.01560.x>.

102.

Frandsen, C.S.S., Madsbad, S.: Efficacy and safety of dipeptidyl peptidase-4 inhibitors as an add-on to insulin treatment in patients with Type 2 diabetes: a review. *Diabetic Medicine*. 31, 1293–1300 (2014). <https://doi.org/10.1111/dme.12561>.

103.

Holman, R.R., Farmer, A.J., Davies, M.J., Levy, J.C., Darbyshire, J.L., Keenan, J.F., Paul, S.K.: Three-Year Efficacy of Complex Insulin Regimens in Type 2 Diabetes. *New England Journal of Medicine*. 361, 1736–1747 (2009). <https://doi.org/10.1056/NEJMoa0905479>.

104.

Rosenstock, J., Jelaska, A., Frappin, G., Salsali, A., Kim, G., Woerle, H.J., Broedl, U.C.: Improved Glucose Control With Weight Loss, Lower Insulin Doses, and No Increased Hypoglycemia With Empagliflozin Added to Titrated Multiple Daily Injections of Insulin in Obese Inadequately Controlled Type 2 Diabetes. *Diabetes Care*. 37, 1815–1823 (2014). <https://doi.org/10.2337/dc13-3055>.

105.

Bergenstal, R.M., Johnson, M., Powers, M.A., Wynne, A., Vlaisnik, A., Hollander, P., Rendell, M.: Adjust to Target in Type 2 Diabetes: Comparison of a simple algorithm with carbohydrate counting for adjustment of mealtime insulin glulisine. *Diabetes Care*. 31, 1305–1310 (2008). <https://doi.org/10.2337/dc07-2137>.

106.

Owens, D.R., Luzio, S.D., Sert-Langeron, C., Riddle, M.C.: Effects of initiation and titration of a single pre-prandial dose of insulin glulisine while continuing titrated insulin glargine in type 2 diabetes: a 6-month 'proof-of-concept' study. *Diabetes, Obesity and Metabolism*. 13, 1020–1027 (2011). <https://doi.org/10.1111/j.1463-1326.2011.01459.x>.

107.

Hannele Yki-Järvinen: Is There Evidence to Support Use of Premixed or Prandial Insulin Regimens in Insulin-Naive or Previously Insulin-Treated Type 2 Diabetic Patients? *Diabetes Care*. 36, (2013). <https://doi.org/doi:10.2337/dcS13-2026>.

108.

Lankisch, M.R., Ferlinz, K.C., Leahy, J.L., Scherbaum, W.A.: Introducing a simplified approach to insulin therapy in type 2 diabetes: a comparison of two single-dose regimens of insulin glulisine plus insulin glargine and oral antidiabetic drugs. *Diabetes, Obesity and Metabolism*. (2008). <https://doi.org/10.1111/j.1463-1326.2008.00967.x>.

109.

Lasserson, D.S., Glasziou, P., Perera, R., Holman, R.R., Farmer, A.J.: Optimal insulin regimens in type 2 diabetes mellitus: systematic review and meta-analyses. *Diabetologia*. 52, 1990–2000 (2009). <https://doi.org/10.1007/s00125-009-1468-7>.

110.

Giugliano, D., Maiorino, M.I., Bellastella, G., Chiodini, P., Ceriello, A., Esposito, K.: Efficacy of Insulin Analogs in Achieving the Hemoglobin A1c Target of <7% in Type 2 Diabetes: Meta-analysis of randomized controlled trials. *Diabetes Care*. 34, 510–517 (2011). <https://doi.org/10.2337/dc10-1710>.

111.

Raccah, D., Huet, D., Dib, A., Joseph, F., Landers, B., Escalada, J., Schmitt, H.: Review of basal-plus insulin regimen options for simpler insulin intensification in people with Type 2 diabetes mellitus. *Diabetic Medicine*. (2017). <https://doi.org/10.1111/dme.13390>.

112.

Raccach, D., Huet, D., Dib, A., Joseph, F., Landers, B., Escalada, J., Schmitt, H.: Review of basal-plus insulin regimen options for simpler insulin intensification in people with Type 2 diabetes mellitus. *Diabetic Medicine*. 34, 1193–1204 (2017).  
<https://doi.org/10.1111/dme.13390>.

113.

Martha M. Funnell: Overcoming barriers to the initiation of insulin therapy. *Clinical Diabetes*.

114.

McBain, H., Begum, S., Rahman, S., Mulligan, K.: Barriers to and enablers of insulin self-titration in adults with Type 2 diabetes: a qualitative study. *Diabetic Medicine*. 34, 253–261 (2017). <https://doi.org/10.1111/dme.13196>.

115.

Manju Chandran, Steven V. Edelman: Have insulin, will fly: diabetes management during air travel and time zone adjustment strategies. (Practical Pointers). *Clinical Diabetes*.

116.

Burnett, J.C.D.: Long- and Short-Haul Travel by Air: Issues for People With Diabetes on Insulin. *Journal of Travel Medicine*. 13, 255–260 (2006).  
<https://doi.org/10.1111/j.1708-8305.2006.00057.x>.

117.

Suggested insulin regimens for patients with type 1 diabetes mellitus who wish to fast during the month of Ramadan - ClinicalKey,  
<https://www-clinicalkey-com.ezproxy3.lib.le.ac.uk/#!/content/journal/1-s2.0-S0149291808002737>.

118.

Hui, E., Bravis, V., Salih, S., Hassanein, M., Devendra, D.: Comparison of Humalog Mix 50 with human insulin Mix 30 in type 2 diabetes patients during Ramadan. *International*

Journal of Clinical Practice. 64, 1095–1099 (2010).  
<https://doi.org/10.1111/j.1742-1241.2010.02347.x>.

119.

Ali, S., Davies, M.J., Brady, E.M., Gray, L.J., Khunti, K., Beshyah, S.A., Hanif, W.: Guidelines for managing diabetes in Ramadan. *Diabetic Medicine*. 33, 1315–1329 (2016).  
<https://doi.org/10.1111/dme.13080>.

120.

Bakiner, O., Ertorer, M.E., Bozkirli, E., Tutuncu, N.B., Demirag, N.G.: Repaglinide plus single-dose insulin glargine: a safe regimen for low-risk type 2 diabetic patients who insist on fasting in Ramadan. *Acta Diabetologica*. 46, 63–65 (2009).  
<https://doi.org/10.1007/s00592-008-0062-7>.

121.

Gregory T. Mucha, Stacia Merkel, William Thomas, John P. Bantle: Fasting and insulin glargine in individuals with type 1 diabetes. *Diabetes Care*.

122.

Diabetes & Metabolism - Présentation - EM consulte,  
<http://www.em-consulte.com/article/80031/alertePM#N1010C>.

123.

Mollema, E.D., Snoek, F.J., Heine, R.J., Van Der Ploeg, H.M.: Phobia of self-injecting and self-testing in insulin-treated diabetes patients: opportunities for screening. *Diabetic Medicine*. 18, 671–674 (2001). <https://doi.org/10.1046/j.1464-5491.2001.00547.x>.

124.

Jenkins, K.: II. Needle phobia: a psychological perspective. *British Journal of Anaesthesia*. 113, 4–6 (2014). <https://doi.org/10.1093/bja/aeu013>.

125.

Zambanini, A., Newson, R.B., Maisey, M., Feher, M.D.: Injection related anxiety in insulin-treated diabetes. *Diabetes Research and Clinical Practice*. 46, 239–246 (1999). [https://doi.org/10.1016/S0168-8227\(99\)00099-6](https://doi.org/10.1016/S0168-8227(99)00099-6).

126.

Mattoo, V., Milicevic, Z., Malone, J.K., Schwarzenhofer, M., Ekangaki, A., Levitt, L.K., Liong, L.H.C., Rais, N., Tounsi, H.: A comparison of insulin lispro Mix25™ and human insulin 30/70 in the treatment of type 2 diabetes during Ramadan. *Diabetes Research and Clinical Practice*. 59, 137–143 (2003). [https://doi.org/10.1016/S0168-8227\(02\)00202-4](https://doi.org/10.1016/S0168-8227(02)00202-4).

127.

Akram, J., De Verga, V., Group, the R.S.: Insulin lispro (Lys(B28), Pro(B29)) in the treatment of diabetes during the fasting month of Ramadan. *Diabetic Medicine*. 16, 867–874 (1999). <https://doi.org/10.1046/j.1464-5491.1999.00164.x>.

128.

Hui, E., Bravis, V., Salih, S., Hassanein, M., Devendra, D.: Comparison of Humalog Mix 50 with human insulin Mix 30 in type 2 diabetes patients during Ramadan. *International Journal of Clinical Practice*. 64, 1095–1099 (2010). <https://doi.org/10.1111/j.1742-1241.2010.02347.x>.

129.

Simmons, J.H., McFann, K.K., Brown, A.C., Rewers, A., Follansbee, D., Temple-Trujillo, R.E., Klingensmith, G.J.: Reliability of the Diabetes Fear of Injecting and Self-Testing Questionnaire in Pediatric Patients With Type 1 Diabetes. *Diabetes Care*. 30, 987–988 (2007). <https://doi.org/10.2337/dc06-1553>.

130.

Crasto, W.: *Handbook of Insulin Therapies*. Adis; 1st ed. 2016 edition (2016).

131.

Lambert, K., Holt, R.I.G.: The use of insulin analogues in pregnancy. *Diabetes, Obesity and Metabolism*. 15, 888–900 (2013). <https://doi.org/10.1111/dom.12098>.

132.

Hyperglycemia and Adverse Pregnancy Outcomes. *New England Journal of Medicine*. 358, 1991–2002 (2008). <https://doi.org/10.1056/NEJMoa0707943>.

133.

Gurwitz, J.H.: Glucocorticoids and the Risk for Initiation of Hypoglycemic Therapy. *Archives of Internal Medicine*. 154, (1994). <https://doi.org/10.1001/archinte.1994.00420010131015>.

134.

Randomized controlled trial of insulin detemir versus NPH for the treatment of pregnant women with diabetes - ClinicalKey, <https://www-clinicalkey-com.ezproxy3.lib.le.ac.uk/#!/content/journal/1-s2.0-S0002937815005931>.

135.

Simmons, L.R., Molyneaux, L., Yue, D.K., Chua, E.L.: Steroid-Induced Diabetes: Is It Just Unmasking of Type 2 Diabetes? *ISRN Endocrinology*. 2012, 1–5 (2012). <https://doi.org/10.5402/2012/910905>.

136.

Riddle, M.C., Rosenstock, J., Vlahjic, A., Gao, L.: Randomized, 1-year comparison of three ways to initiate and advance insulin for type 2 diabetes: twice-daily premixed insulin versus basal insulin with either basal-plus one prandial insulin or basal-bolus up to three prandial injections. *Diabetes, Obesity and Metabolism*. 16, 396–402 (2014). <https://doi.org/10.1111/dom.12225>.

137.

June James: End-of-life care: Anything but a pathway.

138.

Frisch, A., Chandra, P., Smiley, D., Peng, L., Rizzo, M., Gatcliffe, C., Hudson, M., Mendoza, J., Johnson, R., Lin, E., Umpierrez, G.E.: Prevalence and Clinical Outcome of Hyperglycemia in the Perioperative Period in Noncardiac Surgery. *Diabetes Care*. 33, 1783–1788 (2010). <https://doi.org/10.2337/dc10-0304>.

139.

Home, P., Riddle, M., Cefalu, W.T., Bailey, C.J., Bretzel, R.G., del Prato, S., Leroith, D., Schernthaner, G., van Gaal, L., Raz, I.: Insulin Therapy in People With Type 2 Diabetes: Opportunities and Challenges? *Diabetes Care*. 37, 1499–1508 (2014). <https://doi.org/10.2337/dc13-2743>.

140.

Jackson, M.J., Patvardhan, C., Wallace, F., Martin, A., Yusuff, H., Briggs, G., Malik, R.A.: Perioperative management of diabetes in elective patients: a region-wide audit. *British Journal of Anaesthesia*. 116, 501–506 (2016). <https://doi.org/10.1093/bja/aev554>.

141.

Rowles, S., Kilvert, A., Sinclair, A.: ABCD position statement on diabetes and end of life care. *Practical Diabetes International*. 28, 26–27 (2011). <https://doi.org/10.1002/pdi.1547>.

142.

P. Schneiter: Kinetics of dexamethasone-induced alterations of glucose metabolism in healthy humans. *American Journal of Physiology - Endocrinology and Metabolism*. 275, E806–E813 (1998).

143.

Liu, D., Ahmet, A., Ward, L., Krishnamoorthy, P., Mandelcorn, E.D., Leigh, R., Brown, J.P., Cohen, A., Kim, H.: A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy. *Allergy, Asthma & Clinical Immunology*. 9, (2013). <https://doi.org/10.1186/1710-1492-9-30>.

144.

Holman, R.R., Thorne, K.I., Farmer, A.J., Davies, M.J., Keenan, J.F., Paul, S., Levy, J.C.:

Addition of Biphasic, Prandial, or Basal Insulin to Oral Therapy in Type 2 Diabetes. *New England Journal of Medicine*. 357, 1716–1730 (2007).  
<https://doi.org/10.1056/NEJMoa075392>.

145.

Kutz, A., Struja, T., Hausfater, P., Amin, D., Amin, A., Haubitz, S., Bernard, M., Huber, A., Mueller, B., Schuetz, P.: The association of admission hyperglycaemia and adverse clinical outcome in medical emergencies: the multinational, prospective, observational TRIAGE study. *Diabetic Medicine*. (2017). <https://doi.org/10.1111/dme.13325>.

146.

Rowles, S., Kilvert, A., Sinclair, A.: ABCD position statement on diabetes and end of life care. *Practical Diabetes International*. 28, 26–27 (2011). <https://doi.org/10.1002/pdi.1547>.

147.

Tapley, M., Needham, E.: Improving end of life care for people with diabetes. *Practical Diabetes*. 29, 306–307a (2012). <https://doi.org/10.1002/pdi.1711>.

148.

Intensity of peri-operative glycemic control and postoperative outcomes in patients with diabetes: a meta-analysis - ClinicalKey,  
<https://www-clinicalkey-com.ezproxy3.lib.le.ac.uk/#!/content/journal/1-s2.0-S0168822713001873>.

149.

F Game: *Annals of The Royal College of Surgeons of England*. 94, (2012).  
<https://doi.org/doi:10.1308/003588412X13171221591655>.

150.

Hommel, I., van Gurp, P.J., Tack, C.J., Liefers, J., Mulder, J., Wollersheim, H., Hulscher, M.E.J.L.: Perioperative diabetes care: room for improving the person centredness. *Diabetic Medicine*. 32, 561–568 (2015). <https://doi.org/10.1111/dme.12600>.



151.

Aldam, P., Levy, N., Hall, G.M.: Perioperative management of diabetic patients: new controversies. *British Journal of Anaesthesia*. 113, 906–909 (2014).  
<https://doi.org/10.1093/bja/aeu259>.

152.

Barker, P., Creasey, P.E., Dhatariya, K., Levy, N., Lipp, A., Nathanson, M.H., Penfold, N., Watson, B., Woodcock, T.: Peri-operative management of the surgical patient with diabetes 2015. *Anaesthesia*. 70, 1427–1440 (2015). <https://doi.org/10.1111/anae.13233>.

153.

Levy, N., Penfold, N., Mythen, M.: Perioperative management of diabetes and the emerging role of anaesthetists as perioperative physicians. *British Journal of Anaesthesia*. 116, 443–447 (2016). <https://doi.org/10.1093/bja/aew049>.

154.

Bajwa, S., Baruah, M., Kalra, S., Kapoor, M.: Interdisciplinary position statement on management of hyperglycemia in peri-operative and intensive care. *Journal of Anaesthesiology Clinical Pharmacology*. 31, (2015).  
<https://doi.org/10.4103/0970-9185.155141>.

155.

Hwang, J.L., Weiss, R.E.: Steroid-induced diabetes: a clinical and molecular approach to understanding and treatment. *Diabetes/Metabolism Research and Reviews*. 30, 96–102 (2014). <https://doi.org/10.1002/dmrr.2486>.

156.

Gururaj Setty, S., Crasto, W., Jarvis, J., Khunti, K., Davies, M.J.: New insulins and newer insulin regimens: a review of their role in improving glycaemic control in patients with diabetes. *Postgraduate Medical Journal*. 92, 152–164 (2016).  
<https://doi.org/10.1136/postgradmedj-2015-133716>.

157.

Crasto, W.: Handbook of Insulin Therapies. Adis; 1st ed. 2016 edition (2016).

158.

Bergenstal, R.M., Rosenstock, J., Arakaki, R.F., Prince, M.J., Qu, Y., Sinha, V.P., Howey, D.C., Jacober, S.J.: A Randomized, Controlled Study of Once-Daily LY2605541, a Novel Long-Acting Basal Insulin, Versus Insulin Glargine in Basal Insulin-Treated Patients With Type 2 Diabetes. *Diabetes Care*. 35, 2140–2147 (2012). <https://doi.org/10.2337/dc12-0060>.

159.

Rosenstock, J., Bergenstal, R.M., Blevins, T.C., Morrow, L.A., Prince, M.J., Qu, Y., Sinha, V.P., Howey, D.C., Jacober, S.J.: Better Glycemic Control and Weight Loss With the Novel Long-Acting Basal Insulin LY2605541 Compared With Insulin Glargine in Type 1 Diabetes: A randomized, crossover study. *Diabetes Care*. 36, 522–528 (2013). <https://doi.org/10.2337/dc12-0067>.

160.

Riddle, M.C., Bolli, G.B., Ziemien, M., Muehlen-Bartmer, I., Bizet, F., Home, P.D.: New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 2 Diabetes Using Basal and Mealtime Insulin: Glucose Control and Hypoglycemia in a 6-Month Randomized Controlled Trial (EDITION 1). *Diabetes Care*. 37, 2755–2762 (2014). <https://doi.org/10.2337/dc14-0991>.

161.

Home, P.D., Bergenstal, R.M., Bolli, G.B., Ziemien, M., Rojas, M., Espinasse, M., Riddle, M.C.: New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 1 Diabetes: A Randomized, Phase 3a, Open-Label Clinical Trial (EDITION 4). *Diabetes Care*. 38, 2217–2225 (2015). <https://doi.org/10.2337/dc15-0249>.

162.

New Insulin Glargine 300 U/mL: Glycemic Control and Hypoglycemia in a Meta-Analysis of Phase 3a EDITION Clinical Trials in People with T2DM - ClinicalKey, <https://www-clinicalkey-com.ezproxy3.lib.le.ac.uk/#!/content/journal/1-s2.0-S1499267114003086>.

163.

Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with its components given alone: results of a phase 3, open-label, randomised, 26-week, treat-to-target trial in insulin-naive patients with type 2 diabetes - ClinicalKey,  
<https://www-clinicalkey-com.ezproxy4.lib.le.ac.uk/#!/content/journal/1-s2.0-S2213858714701743>.

164.

Buse, J.B., Vilsbøll, T., Thurman, J., Blevins, T.C., Langbakke, I.H., Böttcher, S.G., Rodbard, H.W.: Contribution of Liraglutide in the Fixed-Ratio Combination of Insulin Degludec and Liraglutide (IDegLira). *Diabetes Care*. 37, 2926–2933 (2014).  
<https://doi.org/10.2337/dc14-0785>.

165.

EASD Virtual Meeting,  
<http://www.easdvirtualmeeting.org/resources/systematic-review-and-meta-analysis-of-the-efficacy-and-safety-of-sgl2-inhibitors-in-patients-with-type-2-diabetes-mellitus>.

166.

Prandial inhaled insulin plus basal insulin glargine versus twice daily biaspart insulin for type 2 diabetes: a multicentre randomised trial - ClinicalKey,  
<https://www-clinicalkey-com.ezproxy4.lib.le.ac.uk/#!/content/journal/1-s2.0-S0140673610606320>.

167.

Shosuke Satake, Mary Courtney Moore, Kayano Igawa, Margaret Converse, Benjamin Farmer, Doss W. Neal: Direct and indirect effects of insulin on glucose uptake and storage by the liver. (Original Articles). *Diabetes*.

168.

Khedkar, A., Iyer, H., Anand, A., Verma, M., Krishnamurthy, S., Savale, S., Atignat, A.: A dose range finding study of novel oral insulin (IN-105) under fed conditions in type 2 diabetes mellitus subjects. *Diabetes, Obesity and Metabolism*. 12, 659–664 (2010).

<https://doi.org/10.1111/j.1463-1326.2010.01213.x>.

169.

Luzio, S.D., Dunseath, G., Lockett, A., Broke-Smith, T.P., New, R.R., Owens, D.R.: The glucose lowering effect of an oral insulin (Capsulin) during an isoglycaemic clamp study in persons with type 2 diabetes. *Diabetes, Obesity and Metabolism*. 12, 82–87 (2010).  
<https://doi.org/10.1111/j.1463-1326.2009.01146.x>.

170.

W. Blair Geho: A Single-blind, Placebo-controlled, Dose-ranging Trial of Oral Hepatic-directed Vesicle Insulin Add-on to Oral Antidiabetic Treatment in Patients With Type 2 Diabetes Mellitus. *Journal of Diabetes Science and Technology*. 8, (2014).  
<https://doi.org/doi:10.1177/1932296814524871>.

171.

Morçöl, T., Nagappan, P., Nerenbaum, L., Mitchell, A., Bell, S.J.D.: Calcium phosphate-PEG-insulin-casein (CAPIC) particles as oral delivery systems for insulin. *International Journal of Pharmaceutics*. 277, 91–97 (2004).  
<https://doi.org/10.1016/j.ijpharm.2003.07.015>.

172.

Pozzilli, P., Manfrini, S., Costanza, F., Coppolino, G., Cavallo, M.G., Fioriti, E., Modi, P.: Biokinetics of buccal spray insulin in patients with type 1 diabetes. *Metabolism*. 54, 930–934 (2005). <https://doi.org/10.1016/j.metabol.2005.02.008>.

173.

Guevara-Aguirre, J., Guevara, M., Saavedra, J., Mihic, M., Modi, P.: Beneficial Effects of Addition of Oral Spray Insulin (Oralin) on Insulin Secretion and Metabolic Control in Subjects with Type 2 Diabetes Mellitus Suboptimally Controlled on Oral Hypoglycemic Agents. *Diabetes Technology & Therapeutics*. 6, 1–8 (2004).  
<https://doi.org/10.1089/152091504322783341>.

174.

Kuhlmann, M., Marre, M.: Lessons learned from biosimilar epoetins and insulins. *The British*

Journal of Diabetes & Vascular Disease. 10, 90–97 (2010).  
<https://doi.org/10.1177/1474651409355454>.

175.

Raccah, D., Huet, D., Dib, A., Joseph, F., Landers, B., Escalada, J., Schmitt, H.: Review of basal-plus insulin regimen options for simpler insulin intensification in people with Type 2 diabetes mellitus. *Diabetic Medicine*. 34, 1193–1204 (2017).  
<https://doi.org/10.1111/dme.13390>.

176.

Lea, Mary R. □Creme, Phyllis: *Writing At University*. McGraw-Hill Education (2008).

177.

Bailey, S.: *Academic writing: a handbook for international students*. Routledge, London (2011).